Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-CD19 CART cell therapy - Cellular Biomedicine Group; Anti-CD19 CART cells; C-CAR011; CD19 specific CART cells

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Chinese PLA General Hospital
  • Class Antineoplastics; Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 29 Nov 2016 Efficacy data from a multi-cohort dataset analysis in Diffuse large B cell lymphoma released by Cellular Biomedicine before November 2016
  • 29 Nov 2016 Cellular Biomedicine initiates enrolment in the phase I CARD-1 trial for Diffuse large B cell lymphoma in China
  • 14 Aug 2015 Cellular Biomedicine plans a phase II trial for Haematological malignancies in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top